SEARCH

SEARCH BY CITATION

References

  • 1
    Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer 1974; 34: 153240.
  • 2
    Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 1976; 116: 1803.
  • 3
    Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette-Guérin in the treatment of non muscle invasive bladder cancer. Eur. Urol. 2010; 57: 41029.
  • 4
    Martinez-Pineiro JA, Muntanola P. Non-specific immunotherapy with BCG vaccine in bladder tumors. A preliminary report. Eur. Urol. 1977; 3: 1122.
  • 5
    Martinez-Pineiro JA. BCG vaccine in superficial bladder tumors: eight years later. Eur. Urol. 1984; 10: 93100.
  • 6
    Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guérin for superficial bladder cancer. J. Urol. 1990; 144: 657.
  • 7
    Brosman S. Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. J. Urol. 1982; 128: 2730.
  • 8
    Herr HW, Pinsky CM, Whitmore WF, Oettgen HF, Melamed MR. Effect of intravesical bacillus Calmette-Guérin (BCG) on carcinoma in situ of the bladder. Cancer 1983; 51: 13236.
  • 9
    Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol. 1988; 6: 14505.
  • 10
    Luftnegger W, Ackermann DK, Futterlieb A et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J. Urol. 1996; 155: 4837.
  • 11
    Lamm DL, van der Meijden APM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol. 1992; 147: 596600.
  • 12
    Witjes JA, Palou J, Soloway M et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur. Urol. Suppl. 2008; 7: 66774.
  • 13
    Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side effects management. Eur. Urol. Suppl. 2000; 37: 336.
  • 14
    Van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus Calmette-Guérin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur. Urol. 2003; 44: 42934.
  • 15
    Koga H, Ozono S, Tsushima T et al.; BCG Tokyo Strain Study Group. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int. J. Urol. 2010; 17: 75966.
  • 16
    Vegt PDJ, van der Meijden APM, Sylvester R, Brausi M, Hoeltl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911. J. Urol. 1997; 157: 12469.
  • 17
    Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double blind, placebo controlled, multicenter study. J. Urol. 2006; 176: 9359.
  • 18
    O'Donnell M. Does ofloxacin protect against BCG related toxic effects in patients with bladder cancer? Nat. Clin. Pract. Urol. 2007; 4: 3045.
  • 19
    Martinez-Pineiro JA, Flores N, Isorna S et al. Long-term follow up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002; 89: 67180.
  • 20
    Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3 fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 2005; 174: 124247.
  • 21
    Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate risk superficial bladder cancer: low dose bacillus Calmette-Guérin (27 mg) versus very low dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C. Eur. Urol. 2007; 52: 1398406.
  • 22
    Champetier D, Valignat C, Lopez JG, Ruffion A, Devonec M, Perrin P. BCG thérapie intravésicale: comparaison des effets secondaires des souches Connaught (Toronto) et Pasteur (Paris). Prog. Urol. 2000; 10: 5427.
  • 23
    Fellows GJ, Parmar MK, Grigor KM, Hall RR, Heal MR, Wallace DM. Marker tumor response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumors: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br. J. Urol. 1994; 73: 63944.
  • 24
    Vegt PDJ, Witjes JA, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM. A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin Tice and bacillus Calmette-Guérin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol. 1995; 153: 92933.
  • 25
    Sylvester RJ, van der Meijden APM, Oosterlinck W, Hoeltl W, Bono AV. The side effects of bacillus Calmette-Guérin in the treatment of TaT1 bladder cancer do not predict its efficacy: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur. Urol. 2003; 44: 42328.
  • 26
    Zlotta AR, Van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Eur. Urol. 2000; 37: 4707.
  • 27
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DHJ. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations? J. Urol. 1999; 16: 6771.
  • 28
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guérin determine the succeeding Th1 response. J. Urol. 2003; 170: 20048.
  • 29
    De Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur. Urol. 2005; 48: 3338.
  • 30
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder; a randomized Southwest Oncology Group study. J. Urol. 2000; 163: 11249.
  • 31
    Sylvester RJ, Brausi MA, Kirkels WJ et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isonizid in patients with intermediate and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 2010; 57: 76673.
  • 32
    Herr HW, Morales A. History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J. Urol. 2008; 179: 536.
  • 33
    Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 196470.
  • 34
    Kikuchi E, Fujimoto H, Mizutani Y et al. Cancer Registration Committee of the Japanese Urological Association. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association. Int. J. Urol. 2009; 16: 27986.
  • 35
    Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 46677.
  • 36
    Babjuk M, Oosterlinck W, Sylvester R, Kasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008; 54: 30314.
  • 37
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 231430.
  • 38
    Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J. Urol. 1996; 156: 193441.
  • 39
    Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol. 2000; 53: 67680.
  • 40
    Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21: 76570.
  • 41
    Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 2004; 171: 218690.
  • 42
    Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 1995; 153: 144450.
  • 43
    Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001; 88: 20916.
  • 44
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urol. 2006; 67: 121623.
  • 45
    Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004; 48590.
  • 46
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169: 905.
  • 47
    Sylvester RJ, van der Meijden APM, Wijjes JA, Kurth KH. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2005; 174: 8692.
  • 48
    Malmstrom PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non muscle invasive bladder cancer. Eur. Urol. 2009; 56: 24756.
  • 49
    Herr HW. Is maintenance bacillus Calmette-Guérin really necessary? Eur. Urol. 2008; 54: 9713.
  • 50
    Bohle A, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63: 6827.
  • 51
    Sylvester RJ, van der Meijden APM, Witjes JA et al. High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urol. 2005; 66 (Suppl 6A): 90107.
  • 52
    Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. Int. J. Urol. 2009; 16: 28792.
  • 53
    Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur. Urol. 2004; 45: 2926.
  • 54
    Saint F, Salomon L, Quintela R et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur. Urol. 2003; 43: 35161.
  • 55
    Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non muscle invasive bladder cancer: an update. Can. Urol. Assoc. J. 2009; 3 (Suppl 4): S199205.
  • 56
    Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non muscle invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur. Urol. 2008; 53: 9921002.
  • 57
    Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 2009; 182: 2195203.
  • 58
    Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urol. 2007; 70: 658.
  • 59
    Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J. Urol. 2006; 175: 163440.
  • 60
    Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol. Oncol. 2008; 26: 13740.
  • 61
    Herr HW, Dalbagni G. Defining bacillus Calmette-Guérin refractory superficial tumors. J. Urol. 2003; 169: 17068.
  • 62
    Kim YJ, Ha YS, Kim SK et al. Gene signatures for the prediction of response to bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin. Cancer Res. 2010; 16: 21317.
  • 63
    Lee JS, Leem SH, Lee SY et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 2010; 28: 26607.
  • 64
    Van Rhijn BWG, Zuiverloon TCM, Vis AN et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 2010; 58: 43341.